JP2001512314A - 肺癌用のタンパク質マーカーおよびその使用 - Google Patents
肺癌用のタンパク質マーカーおよびその使用Info
- Publication number
- JP2001512314A JP2001512314A JP53551498A JP53551498A JP2001512314A JP 2001512314 A JP2001512314 A JP 2001512314A JP 53551498 A JP53551498 A JP 53551498A JP 53551498 A JP53551498 A JP 53551498A JP 2001512314 A JP2001512314 A JP 2001512314A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- tumor
- animal
- lung
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 118
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 108
- 208000020816 lung neoplasm Diseases 0.000 title claims description 43
- 206010058467 Lung neoplasm malignant Diseases 0.000 title description 21
- 201000005202 lung cancer Diseases 0.000 title description 21
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 100
- 208000037841 lung tumor Diseases 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims description 63
- 241001465754 Metazoa Species 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 26
- 108010052500 Calgranulin A Proteins 0.000 claims description 15
- 102100032442 Protein S100-A8 Human genes 0.000 claims description 15
- 108010052495 Calgranulin B Proteins 0.000 claims description 14
- 102100032420 Protein S100-A9 Human genes 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 11
- 238000001502 gel electrophoresis Methods 0.000 claims description 8
- 238000010324 immunological assay Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 230000009257 reactivity Effects 0.000 claims description 6
- 239000003053 toxin Substances 0.000 claims description 6
- 231100000765 toxin Toxicity 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims description 5
- 238000005734 heterodimerization reaction Methods 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 5
- 210000004988 splenocyte Anatomy 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 241001669573 Galeorhinus galeus Species 0.000 claims description 2
- 239000000941 radioactive substance Substances 0.000 claims description 2
- 230000005751 tumor progression Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 abstract description 38
- 238000004458 analytical method Methods 0.000 abstract description 8
- 239000000959 ampholyte mixture Substances 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 description 82
- 235000018102 proteins Nutrition 0.000 description 80
- 210000004072 lung Anatomy 0.000 description 54
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 41
- 206010041067 Small cell lung cancer Diseases 0.000 description 37
- 208000000587 small cell lung carcinoma Diseases 0.000 description 37
- 201000005249 lung adenocarcinoma Diseases 0.000 description 35
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 26
- 208000009956 adenocarcinoma Diseases 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 8
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 7
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 201000004101 esophageal cancer Diseases 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012474 protein marker Substances 0.000 description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 101100339887 Drosophila melanogaster Hsp27 gene Proteins 0.000 description 4
- 101150096895 HSPB1 gene Proteins 0.000 description 4
- 208000000172 Medulloblastoma Diseases 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 208000000649 small cell carcinoma Diseases 0.000 description 4
- 208000023514 Barrett esophagus Diseases 0.000 description 3
- 208000023665 Barrett oesophagus Diseases 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001155 isoelectric focusing Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 102220201851 rs143406017 Human genes 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 101710095306 Alpha-crystallin Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 101000604054 Homo sapiens Neuroplastin Proteins 0.000 description 1
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710164418 Movement protein TGB2 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000979628 Mus musculus Nucleoside diphosphate kinase A Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100038434 Neuroplastin Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710147950 P18 protein Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 201000008183 Pulmonary blastoma Diseases 0.000 description 1
- 102100021225 Serine hydroxymethyltransferase, cytosolic Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000025402 neoplasm of esophagus Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- OCQZXMCGTAWGEQ-UHFFFAOYSA-N prop-2-enamide;n-[(prop-2-enoylamino)methyl]prop-2-enamide Chemical compound NC(=O)C=C.C=CC(=O)NCNC(=O)C=C OCQZXMCGTAWGEQ-UHFFFAOYSA-N 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. スポット14、15、16、17、21、22、27、29、31、33、40、42、43、47、50、 53、57、58、59、61、62、66、68、73、74、79、81、83、84、86、90、94、95、 96、97、98、100、101、102、105および106からなる群から選ばれる非−腫瘍組 織と比較して、肺腫瘍中で過度に発現されるタンパク。 2. 請求の範囲第1項に記載のタンパクと特異的に結合する、抗体または抗原と 結合するそのフラグメント。 3. 肺腫瘍のサブタイプを確立し、もしくは肺腫瘍の進行を追跡するためのスク リーニング法であって、 a)動物もしくはヒト中の、または動物もしくはヒト由来のサンプル中の、スポ ット14、15、16、17、21、22、27、29、31、33、40、42、43、47、50、53、57、 58、59、61、62、66、67、68、73、74、79、80、81、83、84、86、90、92、94、 95、96、97、98、100、101、102、105、106、107および109からなる群から選ば れる、少なくとも1種のタンパクの量を測定し、そして b)肺腫瘍の存在、そのサブタイプ、またはその段階と、該タンパク量とを相関 させる工程を含むことを特徴とする上記方法。 4. 該タンパクの量を免疫学的アッセイにより測定する請求の範囲第3項に記載 の方法。 5. 該タンパクの量を2-Dゲル電気泳動により測定する請求の範囲第3項に記載 の方法。 6. 該少なくとも1種のタンパクが、動物もしくはヒト中の、または動物もしく はヒト由来のサンプル中のスポット14、15、16、17、21,22、27、29、31、33、 40、42、43、47、50、53、57、58、59、61、62、66、67、68、73、74、79、80、 81、83、84、86、90、92、94、95、96、97、98、100、101、102、105、106、107 および109からなる群から選ばれる複数のタンパクである請求の範囲第3項に記 載の方法。 7. 該タンパクの量を、免疫学的アッセイにより測定する、請求の範囲第6項に 記載の方法。 8. 該タンパクの量を2-Dゲル電気泳動により測定する請求の範囲第6項に記載 の方法。 9. 請求の範囲第1項に記載のタンパクと特異的に結合する、抗体または抗原と 結合するそのフラグメントの製造法であって、 a)動物を請求の範囲第1項に記載のタンパクで免疫し、 b)該動物から血清を採取し、そして c)該血清から、請求の範囲第1項に記載のタンパクと特異的に結合する、抗体 または抗原と結合するそのフラグメントを単離する工程を含むことを特徴とする 上記方法。 10.請求の範囲第1項に記載のタンパクと特異的に結合する、モノクローナル抗 体または抗原と結合するそのフラグメントの製造法であって、 a)動物を請求の範囲第1項に記載のタンパクで免疫し、 b)該動物から脾細胞を単離し、 c)該脾細胞をミエローマ細胞と融合し、 d)該融合細胞を育成し、 e)該融合細胞を、請求の範囲第1項に記載のタンパクと特異的に結合する抗体 についてテストし、そして f)請求の範囲第1項に記載のタンパクと特異的に結合する、任意の抗体または 抗原と結合するそのフラグメントを単離する工程を含むことを特徴とする上記方 法。 11.組織部分における腫瘍組織の検出方法であって、 a)組織部分を、MRP8およびMRP14のヘテロダイマー化により形成されるエピト ープに対して特異的な抗体で処理し、 b)任意の未結合抗体を洗い流し、そして c)腫瘍組織の存在に関する指標として、該組織部分における結合抗体の量を測 定する工程を含むことを特徴とする上記方法。 12.該腫瘍が肺腫瘍である請求の範囲第11項に記載の方法。 13.動物またはヒト内の腫瘍の検出方法であって、 a)該動物またはヒト由来の血清サンプル中のタンパクを分離し、 b)該タンパクを膜に転写し、 c)該タンパクを、MRP8およびMRP14のヘテロダイマー化により形成されるエピ トープに対して特異的な抗体を使用して精査し、 d)結合した抗体の量を測定し、 e)バンド内の反応性の強度を積分し、そして f)該積分強度と、腫瘍の存在または段階とを相関付ける工程を含むことを特徴 とする上記方法。 14.該腫瘍が肺腫瘍である請求の範囲第13項に記載の方法。 15.該バンドが14kDaである請求の範囲第14項に記載の方法。 16.請求の範囲第1項記載のタンパクをコード化する単離された遺伝子であって 、該タンパクが、a)配列番号(Seq.ID No.)1、b)配列番号(Seq.ID No.)2、c )配列番号(Seq.ID No.)5、d)配列番号(Seq.ID No.)6およびe)配列番号(Seq.I D No.)8からなる群から選ばれるアミノ酸配列を含むことを特徴とする上記単離 遺伝子。 17.治療を必要とする動物またはヒトにおける腫瘍を治療する方法であって、 a)請求の範囲第2項に記載の抗体または抗原と結合するそのフラグメントを、 放射性物質、毒素または抗−腫瘍薬物と複合化し、そして b)該複合体の有効量を該動物またはヒトに投与する工程を含むことを特徴とす る上記方法。 18.治療を必要とする動物またはヒトにおける腫瘍を治療する方法であって、 a)該動物またはヒト由来の免疫担当細胞を、スポット14、15、16、17、21、22 、27、29、31、33、40、42、43、47、50、53、57、58、59、61、62、66、67、68 、73、74、79、80、81、83、84、86、90、92、94、95、96、97、98、100、101、 102、105、106、107および109からなる群から選ばれる少なくとも1種のタンパ クに暴露し、そして b)該免疫担当細胞を、該動物またはヒトに注入して腫瘍を治療する工程を含む ことを特徴とする上記方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3881997P | 1997-02-12 | 1997-02-12 | |
US60/038,819 | 1997-02-12 | ||
PCT/IB1998/000361 WO1998035985A1 (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001512314A true JP2001512314A (ja) | 2001-08-21 |
JP4367866B2 JP4367866B2 (ja) | 2009-11-18 |
Family
ID=21902087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53551498A Expired - Fee Related JP4367866B2 (ja) | 1997-02-12 | 1998-02-12 | 肺癌用のタンパク質マーカーおよびその使用 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20020192228A1 (ja) |
EP (1) | EP0961780B1 (ja) |
JP (1) | JP4367866B2 (ja) |
AT (1) | ATE359515T1 (ja) |
AU (1) | AU6111298A (ja) |
CA (1) | CA2280930C (ja) |
DE (1) | DE69837529T2 (ja) |
DK (1) | DK0961780T3 (ja) |
ES (1) | ES2284200T3 (ja) |
NZ (1) | NZ337750A (ja) |
WO (1) | WO1998035985A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7670789B2 (en) | 2004-07-23 | 2010-03-02 | Aspenbio Pharma, Inc. | Methods and devices for diagnosis of appendicitis |
JP2010539486A (ja) * | 2007-09-11 | 2010-12-16 | キャンサー・プリヴェンション・アンド・キュア,リミテッド | ヒト肺組織の病態を示すヒト血清中のタンパク質の同定 |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6531315B1 (en) | 1998-03-18 | 2003-03-11 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6696247B2 (en) | 1998-03-18 | 2004-02-24 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
US6960570B2 (en) | 1998-03-18 | 2005-11-01 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6518256B1 (en) | 1998-03-18 | 2003-02-11 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
US6426072B1 (en) | 2000-08-02 | 2002-07-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6706262B1 (en) | 1998-03-18 | 2004-03-16 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
US7579160B2 (en) | 1998-03-18 | 2009-08-25 | Corixa Corporation | Methods for the detection of cervical cancer |
US6660838B1 (en) | 1998-03-18 | 2003-12-09 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
US6312695B1 (en) | 1998-03-18 | 2001-11-06 | Corixa Corporation | Compounds and methods for therapy of lung cancer |
US7049063B2 (en) | 1998-03-18 | 2006-05-23 | Corixa Corporation | Methods for diagnosis of lung cancer |
US7258860B2 (en) | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6482597B1 (en) | 1999-12-17 | 2002-11-19 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
US6737514B1 (en) | 1998-12-22 | 2004-05-18 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6821518B1 (en) | 1998-03-18 | 2004-11-23 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
CA2349593A1 (en) * | 1998-11-05 | 2000-05-11 | The Regents Of The University Of Michigan | S100 proteins and autoantibodies as serum markers for cancer |
AU2004201392B2 (en) * | 1998-11-05 | 2007-06-14 | The Regents Of The University Of Michigan | S100 proteins and autoantibodies as serum markers for cancer |
ES2308976T3 (es) * | 1999-04-02 | 2008-12-16 | Corixa Corporation | Compuestos y metodos para la terapia y el diagnostico del cancer de pulmon. |
AU2002246668A1 (en) * | 2000-11-02 | 2002-07-30 | Molecular Discoveries, L.L.C. | Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc) |
EP1373896A2 (en) * | 2001-03-12 | 2004-01-02 | MonoGen, Inc. | Cell-based detection and differentiation of disease states |
CA2489860C (en) * | 2002-07-05 | 2015-02-10 | Universite Laval | Use of an antibody against s100a8 or s100a9 as chemotactic factor inhibitor for modulating inflammatory reactions |
AU2002951153A0 (en) * | 2002-09-02 | 2002-09-19 | Proteome Systems Intellectual Property Pty Ltd | An electrophoresis gel having improved swelling properties |
CA2565872C (en) * | 2004-05-11 | 2016-06-21 | Abgenomics Corporation | T-cell death-inducing epitopes |
CA2573596A1 (en) * | 2004-07-13 | 2006-01-19 | Universite Laval | S100 protein inhibitors for treating leukemia |
US7659087B2 (en) * | 2004-07-23 | 2010-02-09 | Aspenbio Pharma, Inc. | Methods and devices for diagnosis of appendicitis |
ES2333182T3 (es) | 2005-05-18 | 2010-02-17 | Array Biopharma, Inc. | Derivados de 4-(fenilamino)-6-oxo-1,6-dihidropiridazina-3-carboxamida como inhibidores de mek para el tratamiento de enfermedades hiperproliferativas. |
KR100732298B1 (ko) * | 2005-11-24 | 2007-06-25 | 이화여자대학교 산학협력단 | 유비키틴 c-말단 가수분해제-l1을 이용한 암전이 진단용조성물 |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
SI2057156T1 (sl) * | 2006-08-23 | 2017-06-30 | Kudos Pharmaceuticals Limited | Derivati 2-metilmorfolin pirido-, pirazo- in pirimido-pirimidina kot inhibitorji mTOR |
US8044056B2 (en) | 2007-03-20 | 2011-10-25 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound |
AR065784A1 (es) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
AU2008309383B2 (en) | 2007-10-11 | 2012-04-19 | Astrazeneca Ab | Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors |
PE20131210A1 (es) | 2007-12-19 | 2013-10-31 | Genentech Inc | Derivados de 5-anilinoimidazopiridina como inhibidores de mek |
CA2708176A1 (en) | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Azaindolizines and methods of use |
CA2735900A1 (en) | 2008-09-19 | 2010-03-25 | Medimmune, Llc | Antibodies directed to dll4 and uses thereof |
US20110053923A1 (en) | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
JP2012513194A (ja) | 2008-12-23 | 2012-06-14 | アストラゼネカ アクチボラグ | α5β1に向けられた標的結合剤およびその使用 |
EP3100745B1 (en) | 2009-02-05 | 2018-04-18 | Immunogen, Inc. | Novel benzodiazepine derivatives |
CN104535765A (zh) | 2009-03-12 | 2015-04-22 | 癌症预防和治疗有限公司 | 鉴定、评估、预防以及治疗肺疾病的方法及试剂盒 |
WO2010103094A1 (en) | 2009-03-13 | 2010-09-16 | Cellzome Limited | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
CA2758614A1 (en) | 2009-04-14 | 2010-10-21 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
CA2771675A1 (en) | 2009-09-11 | 2011-03-17 | Cellzome Limited | Ortho substituted pyrimidine compounds as jak inhibitors |
CN102666545B (zh) | 2009-10-20 | 2016-04-06 | 塞尔卓姆有限公司 | 作为jak抑制剂的杂环吡唑并嘧啶类似物 |
EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
JP2013512859A (ja) | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | トール様受容体(tlr)を介して作用するイミダゾキノリン |
EP2521920A4 (en) * | 2010-01-08 | 2013-06-05 | Univ California | PROTEIN MARKERS FOR DETECTION OF LUNG CANCER AND METHODS OF USE THEREOF |
EP2533810B1 (en) | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Cd20 antibodies and uses thereof |
ES2535116T3 (es) | 2010-03-04 | 2015-05-05 | Cellzome Limited | Derivados de urea sustituida con morfolino como inhibidores de mtor |
JP2013525392A (ja) | 2010-04-30 | 2013-06-20 | セルゾーム リミティッド | Jak阻害剤としてのピラゾール化合物 |
SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
WO2012000970A1 (en) | 2010-07-01 | 2012-01-05 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
JP2013534233A (ja) | 2010-08-20 | 2013-09-02 | セルゾーム リミティッド | 選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体 |
CA2815330A1 (en) | 2010-11-09 | 2012-05-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
MY183977A (en) | 2011-02-15 | 2021-03-17 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
CA2827172C (en) | 2011-02-17 | 2019-02-26 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
JP5937111B2 (ja) | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited | Fak阻害剤 |
US20140163023A1 (en) | 2011-04-04 | 2014-06-12 | Cellzome Limited | Dihydropyrrolo pyrimidine derivatives as mtor inhibitors |
WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
AU2012288892B2 (en) | 2011-07-28 | 2016-04-21 | Cellzome Limited | Heterocyclyl pyrimidine analogues as JAK inhibitors |
WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
EP2760863A1 (en) | 2011-09-20 | 2014-08-06 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors |
AU2012311458B2 (en) | 2011-09-21 | 2016-02-04 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mTOR inhibitors |
US9242993B2 (en) | 2011-10-07 | 2016-01-26 | Cellzome Limited | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors |
US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
CN104169272A (zh) | 2011-12-23 | 2014-11-26 | 赛尔佐姆有限公司 | 作为激酶抑制剂的嘧啶-2,4-二胺衍生物 |
EP3505534A1 (en) | 2012-06-08 | 2019-07-03 | Sutro Biopharma, Inc. | Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use |
ES2611788T3 (es) | 2012-06-26 | 2017-05-10 | Sutro Biopharma, Inc. | Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso |
CA2882158A1 (en) | 2012-08-17 | 2014-02-20 | Cancer Therapeutics Crc Pty Limited | Vegfr3 inhibitors |
WO2014031566A1 (en) | 2012-08-22 | 2014-02-27 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
BR112015004022B1 (pt) | 2012-08-31 | 2023-04-25 | Sutro Biopharma, Inc | Aminoácidos modificados compreendendo um grupo azido |
WO2014041349A1 (en) | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
WO2014134486A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
JP6494533B2 (ja) | 2013-02-28 | 2019-04-03 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体 |
AR095443A1 (es) | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | Heterociclos condensados con acción sobre atr |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
SG11201806419RA (en) | 2016-01-27 | 2018-08-30 | Sutro Biopharma Inc | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
CN107459519A (zh) | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
AU2017321973A1 (en) | 2016-09-02 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
US10287253B2 (en) | 2016-12-05 | 2019-05-14 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
CN110709936A (zh) | 2017-04-04 | 2020-01-17 | 肺癌蛋白质组学有限责任公司 | 用于早期肺癌预后的基于血浆的蛋白质概况分析 |
WO2019023316A1 (en) | 2017-07-26 | 2019-01-31 | Sutro Biopharma, Inc. | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA |
US20200353076A1 (en) | 2017-09-18 | 2020-11-12 | Sutro Biopharma, Inc. | Anti-folate receptor alpha antibody conjugates and their uses |
NL2019801B1 (en) | 2017-10-25 | 2019-05-02 | Univ Leiden | Delivery vectors |
CN112513031A (zh) | 2018-06-04 | 2021-03-16 | 阿普罗斯治疗公司 | 可用于治疗与tlr7调节相关的疾病的含酸性基团的嘧啶化合物 |
GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
US20220047716A1 (en) | 2018-09-17 | 2022-02-17 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
EP3962951A1 (en) | 2019-05-03 | 2022-03-09 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
CA3152674A1 (en) | 2019-08-31 | 2021-03-04 | Etern Biopharma (Shanghai) Co., Ltd. | Pyrazole derivatives for fgfr inhibitor and preparation method thereof |
WO2021178597A1 (en) | 2020-03-03 | 2021-09-10 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
TW202408589A (zh) | 2022-06-30 | 2024-03-01 | 美商舒卓生物製藥公司 | 抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物,及製造及使用抗ror1抗體及抗體結合物之方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5019497A (en) * | 1984-11-09 | 1991-05-28 | Lennart Olsson | Human squamous lung carcinoma cell specific antigens and antibodies |
DK276185D0 (da) * | 1984-11-09 | 1985-06-19 | Novo Industri As | Monoklonale antistoffer,fremgangsmaade til fremstilling af disse samt deres diagnostiske anvendelse |
US5171665A (en) * | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
CH685959A5 (de) * | 1992-08-24 | 1995-11-15 | Biomedicals Ag | Diagnostische Testpackung zur Bestimmung von Proteinen. |
EP0695760A1 (en) * | 1994-08-05 | 1996-02-07 | F. Hoffmann-La Roche Ag | Novel tumor marker for lung cancer |
US6107103A (en) * | 1996-10-15 | 2000-08-22 | Procyon Bropharma Inc. | Assay for PSP94 protein |
-
1998
- 1998-02-12 JP JP53551498A patent/JP4367866B2/ja not_active Expired - Fee Related
- 1998-02-12 DE DE69837529T patent/DE69837529T2/de not_active Expired - Lifetime
- 1998-02-12 AT AT98905576T patent/ATE359515T1/de active
- 1998-02-12 AU AU61112/98A patent/AU6111298A/en not_active Abandoned
- 1998-02-12 EP EP98905576A patent/EP0961780B1/en not_active Expired - Lifetime
- 1998-02-12 WO PCT/IB1998/000361 patent/WO1998035985A1/en active IP Right Grant
- 1998-02-12 NZ NZ337750A patent/NZ337750A/en not_active IP Right Cessation
- 1998-02-12 CA CA2280930A patent/CA2280930C/en not_active Expired - Fee Related
- 1998-02-12 DK DK98905576T patent/DK0961780T3/da active
- 1998-02-12 US US09/022,527 patent/US20020192228A1/en not_active Abandoned
- 1998-02-12 ES ES98905576T patent/ES2284200T3/es not_active Expired - Lifetime
-
2003
- 2003-06-16 US US10/461,424 patent/US20050095249A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7670789B2 (en) | 2004-07-23 | 2010-03-02 | Aspenbio Pharma, Inc. | Methods and devices for diagnosis of appendicitis |
JP2010539486A (ja) * | 2007-09-11 | 2010-12-16 | キャンサー・プリヴェンション・アンド・キュア,リミテッド | ヒト肺組織の病態を示すヒト血清中のタンパク質の同定 |
Also Published As
Publication number | Publication date |
---|---|
WO1998035985A1 (en) | 1998-08-20 |
US20020192228A1 (en) | 2002-12-19 |
EP0961780B1 (en) | 2007-04-11 |
AU6111298A (en) | 1998-09-08 |
CA2280930C (en) | 2010-04-06 |
DE69837529D1 (de) | 2007-05-24 |
US20050095249A1 (en) | 2005-05-05 |
DK0961780T3 (da) | 2007-08-27 |
DE69837529T2 (de) | 2007-07-26 |
ATE359515T1 (de) | 2007-05-15 |
CA2280930A1 (en) | 1998-08-20 |
EP0961780A1 (en) | 1999-12-08 |
JP4367866B2 (ja) | 2009-11-18 |
ES2284200T3 (es) | 2007-11-01 |
NZ337750A (en) | 2001-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001512314A (ja) | 肺癌用のタンパク質マーカーおよびその使用 | |
Sörensen et al. | Measuring HER2-receptor expression in metastatic breast cancer using [68Ga] ABY-025 Affibody PET/CT | |
US7326529B2 (en) | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer | |
US7364862B2 (en) | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer | |
CN105026422B (zh) | Sh2结构域变体 | |
AU2010268979B2 (en) | New tumor marker | |
Guan et al. | Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo | |
KR20220083785A (ko) | 인간화 항체 및 그 사용 방법 | |
JP5796008B2 (ja) | 壊死マーカーERp29に対するモノクローナル抗体及びその用途 | |
US9815906B2 (en) | Method of inhibiting or treating cancer metastasis | |
EP1796723B1 (en) | Method of diagnosing cancer by detecting the expression of spag9 or the presence of anti-spag9 antibodies | |
AU768688B2 (en) | Protein markers for lung cancer and use thereof | |
US7326402B2 (en) | Method of diagnosing, monitoring, staging, imaging and treating cancer | |
JP3524536B2 (ja) | 癌の診断、モニタリング、ステージング、イメージングおよび処置のための新規方法 | |
CA2714880C (en) | A novel tumor biomarker | |
JP2005538931A (ja) | ラムノース結合タンパク質 | |
AU2014203702B2 (en) | New tumor marker | |
KR101679245B1 (ko) | 상피성장인자 수용체를 표적으로 하는 암 진단 또는 영상화용 조성물 | |
JP2003512391A (ja) | 核マトリクスタンパク質、それらをコードするポリヌクレオチド配列およびその用途 | |
JP2001523087A (ja) | 腎核マトリックスタンパク質、それらをコードするポリヌクレオチド配列およびそれらの用途 | |
CA2394914A1 (en) | A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050202 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070518 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070619 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071219 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080729 |
|
A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20081111 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081209 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090309 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090427 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090608 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090728 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090824 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120904 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130904 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |